RNA evidence supports clinical stage antibody drug targets in oncology
Background: The selection of efficacious and safe antibody-based oncology targets depends on tumor specificity and normal-tissue expression, and remains challenging. Bulk RNA-seq can identify tumor-enriched surface genes, but may obscure tumor specificity and normal-cell expression patterns that are relevant to the therapeutic window. We evaluated whether single-cell RNA-seq-derived expression…
We haven't written up this one. bioRxiv has the full story — the link below goes straight to it.
